文献速递肾癌与肾肿瘤

临床T1b肾细胞癌:微波消融与手术的结局比较

Comparing Outcomes for Patients with Clinical T1b Renal Cell Carcinoma Treated With Either Percutaneous Microwave Ablation or Surgery.
PubMed 文献 · Urology · 2019-10-01

该单中心回顾性研究纳入2000–2018年325例cT1b非转移性肾细胞癌患者(MW 40例、PN 74例、RN 211例),比较围手术期与肿瘤学结局。MW患者年龄更大、合并症指数更高,住院中位1天短于手术组4天;三组5年无转移生存与癌症特异性生存无差异。结论认为MW是选择性合并症cT1b患者可行的替代方案。

要点

  • MW患者年龄更大、Charlson合并症指数更高,住院中位1天显著短于手术组4天。
  • 三组5年无转移生存与癌症特异性生存无差异,MW组10%发生高级别并发症。

核心结论

  • 微波消融是选择性合并症cT1b肾细胞癌患者可行的手术替代方案。

研究设计与样本

  • 单中心回顾性研究,收集2000–2018年325例cT1b非转移性肾细胞癌患者资料,其中MW 40例、PN 74例、RN 211例。

主要发现

  • MW组住院中位1天,短于手术组4天(P<.0001)。
  • MW组治疗后eGFR中位下降4.5%,PN组下降3.2%(P=.58),RN组下降29%(P<.001)。
  • MW、PN、RN中位随访分别为34、35、49个月。
  • 5年局部无复发生存率MW 94.5% vs PN 97.9%(P=.34),vs RN 99.2%(P=.02)。
  • MW后2例复发并接受重复消融且后续无复发;三组5年无转移生存与癌症特异性生存无差异。

临床怎么用

  • 对合并症较多、手术风险高的选择性cT1b肾细胞癌患者,可考虑微波消融作为替代治疗。
  • MW局部无复发生存低于RN但与PN无差异,需结合患者预期寿命与合并症个体化选择。
  • 有既往腹部手术史者MW高级别并发症风险升高(OR 6.29),术前应充分评估。

局限性

  • 为单中心回顾性研究,MW组仅40例且患者年龄与合并症基线不同于手术组,存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare perioperative and oncologic outcomes for patients with clinical T1b renal cell carcinoma following treatment with microwave ablation (MW), partial nephrectomy (PN), or radical nephrectomy (RN). METHODS: Comprehensive clinical and pathologic data were collected for nonmetastatic renal cell carcinoma patients with cT1b tumors following MW, PN, or RN from 2000 to 2018. Local recurrence-free, metastasis-free, cancer-specific and overall survival were estimated using Kaplan-Meier method. Prognostic factors for complications and survival were determined using logistic regression and Cox hazard models, respectively. RESULTS: A total of 325 patients (40 MW, 74 PN, and 211 RN) were identified. Patients treated with MW were older with higher Charlson comorbidity indices compared to surgical patients. Median length of hospitalization was shorter for MW compared to surgical patients (1 day vs 4 days, P <.0001). Post-treatment estimated glomerular filtration rate decreased by median 4.5% for MW compared to 3.2% for PN (P = .58) and 29% for RN (P <.001). Median follow-up was 34, 35, and 49 months following MW, PN, and RN, respectively. Estimated 5-year local recurrence-free survival was 94.5% for MW vs 97.9% for PN (P = .34) and 99.2% for RN (P = .02). Two patients recurred after MW and underwent repeat ablation without subsequent recurrence. No difference in 5-year metastasis-free survival or cancer-specific survival was found among MW, PN, or RN. Four (10%) MW patients had high-grade complication. Only prior abdominal surgery predicted high-grade complication (OR 6.29, P = .017). CONCLUSION: Microwave ablation is a feasible alternative to surgery in select comorbid patients with clinical T1b renal cell carcinoma.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Shapiro DD, Wells SA, Best SL, et al. Comparing Outcomes for Patients with Clinical T1b Renal Cell Carcinoma Treated With Either Percutaneous Microwave Ablation or Surgery. Urology. 2019. PMID: 31585198. doi:10.1016/j.urology.2019.09.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。